July 7, 2016
(STAT News) – Juno Therapeutics, a pioneer in the sizzling field of treating cancer by revving up the immune system, on Thursday said it had halted development of its lead treatment after three patient deaths, dealing a blow to a promising but still unproven approach to oncology. The treatment, dubbed JCAR015, is created by harvesting a patient’s own immune cells and rewiring them to home in on cancer in the blood. Three patients died after excess fluids accumulated in their brains, Juno said.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.